Approved Oncology Drugs

As a result of our clinical research program, we are proud to be a part of the FDA approval of the following oncology/hematology drugs.

2016

  • Rubraca – (rucaparib); Clovis Oncology; For the treatment of women with a certain type of ovarian cancer
  • Lartruvo – (olaratumab); Eli Lilly; For the treatment of adults with certain types of soft tissue sarcoma
  • Tecentriq – (atezolizumab); Genentech; For the treatment of urothelial carcinoma, the most common type of bladder cancer
  • Venclexta – (venetoclax); Abbvie and Genetech; For the treatment of chronic lymphocytic leukemia in patients with a specific chromosomal abnormality

2015

  • Cotellic – (cobimetinib); Genentech; For the treatment of BRAF V600E or V600K melanoma, Approved November 2015
  • Darzalex- (daratumumab); Janssen Biotech; For the treatment of multiple myeloma, Approved November 2015
  • Imlygic – (talimogene laherparepvec); Amgen; For the treatment of unresectable recurrent melanoma, Approved October 2015
  • Lonsurf – (trifluridine and tipiracil); Taiho Oncology; For the treatment of metastatic colorectal cancer , Approved September 2015
  • Opdivo – (nivolumab); Bristol-Myers Squibb; For the treatment of metastatic squamous non-small cell lung cancer, Approved March 2015

2014

  • Azynzeo – (netupitant and palonosetron);Helsinn; For the prevention of chemotherapy-induced nausea and vomiting, Approved October 2014
  • Imbruvica – (ibrutunib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014
  • Lynparza – (olaparib); AstraZeneca; For the treatment of previously treated BRCA mutated advanced ovarian cancer, Approved December 2014
  • Opdivo – (nivolumab); Bristol-Myers Squibb; For the treatment of unresectable or metastatic melanoma, Approved December 2014
  • Zydelig – (idelalisib);Gilead; For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma, Approved July 2014

2013

  • Gilotrif – (afatinib); Boehringer Ingelheim; For the treatment of metastatic non-small cell lung cancer with EGFR mutations
  • Imbruvica – (ibrutinib);Pharmacyclics; For the treatment of mantle cell lymphoma, Approved November of 2013
  • Pomalyst – (pomalidomide); Celgene; For the treatment of relapsed and refractory multiple myeloma
  • Stivarga – (regorafenib); Bayer; For the treatment of gastrointestinal stromal tumor

2012

  • Subsys – (fentanyl sublingual spray); Insys Therapeutics; For the treatment of breakthrough cancer pain
  • Pertuzumab – (perjeta); Roche; For the treatment of HER2-positive metastatic breast cancer
  • Carfilzomib – (kyprolis); Onyx Pharmaceuticals; For the treatment of multiple myeloma
  • Ziv-aflibercept – (zaltrap); Sanofi; For the treatment of metastatic colorectal cancer

2011

  • Lazanda – (fentanyl citrate) nasal spray; Archimedes; For the management of breakthrough cancer pain
  • Zytiga – (abiraterone acetate); Centocor Ortho Biotech; For the treatment of prostate cancer

2010

  • Halaven – (eribulin mesylate); Eisai; For the treatment of metastatic breast cancer
  • Jevtana – (cabazitaxel) ; Sanofi Aventis; For the treatment of prostate cancer

2009

  • Onsolis – (fentanyl buccal); BioDelivery Sciences; For the management of breakthrough cancer pain
  • Afinitor – (everolimus); Novartis; For the treatment of renal cell carcinoma
  • Folotyn– (pralatrexate injection); Allos Therapeutics; For the treatment of peripheral T-cell lymphoma

2008

  • Sancuso – (granisetron); ProStrakan; For the treatment of chemotherapy-induced nausea and vomiting

2006

  • Sutent– (sunitinib); Pfizer; For the treatment of kidney cancer and gastrointestinal stromal tumors

2005

  • Nexavar – (sorafenib); Bayer/Onyx; For the treatment of Renal Cell Carcinoma

 

Return to Clinical Trials